Proteomics analysis of bladder cancer invasion: Targeting EIF3D for therapeutic intervention

scientific article published on 20 April 2017

Proteomics analysis of bladder cancer invasion: Targeting EIF3D for therapeutic intervention is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.18632/ONCOTARGET.17279
P932PMC publication ID5642490
P698PubMed publication ID29050215

P50authorKonstantinos StravodimosQ118869094
Manousos MakridakisQ118869345
Antonia VlahouQ44903968
Jerome ZoidakisQ52729662
Vasiliki LygirouQ59693741
Maria FrantziQ61793606
Harald MischakQ37828676
P2093author name stringWalter Kolch
Agnieszka Latosinska
Axel S Merseburger
Ioannis Katafigiotis
William Mullen
Maria G Roubelakis
Marie C Hupe
Maciej Dobrzynski
Marika Mokou
P2860cites workProteomic-based approach for biomarkers discovery in early detection of invasive urothelial carcinomaQ82775285
Clinical significance of T-cadherin tissue expression in patients with bladder transitional cell carcinomaQ83254150
Bladder cancerQ84058686
The role of actinin-4 in bladder cancer invasionQ84998833
On Molecular Classification of Bladder Cancer: Out of One, ManyQ85657356
eIF3a is over-expressed in urinary bladder cancer and influences its phenotype independent of translation initiationQ87459522
EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016Q87711943
The star chart to Ta bladder cancer: an unsophisticated analysis of two-dimensional gel electrophoresis proteome mapsQ39911414
Cell surface associated alpha-L-fucose moieties modulate human breast cancer neoplastic progressionQ39972461
Brox, a novel farnesylated Bro1 domain-containing protein that associates with charged multivesicular body protein 4 (CHMP4).Q40026149
Proteomics identification of PGAM1 as a potential therapeutic target for urothelial bladder cancerQ40224310
Subsequent activation of mitogen-activated protein kinase after adhesion of transitional cell cancer cells to fibronectinQ40709713
Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study.Q40828142
An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer.Q40912134
Independent component analysis uncovers the landscape of the bladder tumor transcriptome and reveals insights into luminal and basal subtypesQ41747556
Eukaryotic initiation factor-4E in superficial and muscle invasive bladder cancer and its correlation with vascular endothelial growth factor expression and tumour progressionQ42136215
Annexin-I overexpression is associated with tumour progression and independently predicts inferior disease-specific and metastasis-free survival in urinary bladder urothelial carcinomaQ44824913
Increased expression of α-actinin-4 is associated with unfavorable pathological features and invasiveness of bladder cancerQ45224467
Cathepsin E, maspin, Plk1, and survivin are promising prognostic protein markers for progression in non-muscle invasive bladder cancer.Q53177490
EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines.Q54391399
Prediction of Muscle-invasive Bladder Cancer Using Urinary ProteomicsQ57712052
Platelet-Rich Plasma (PRP) Promotes Fetal Mesenchymal Stem/Stromal Cell Migration and Wound Healing ProcessQ61281064
Expression of thymidine phosphorylase as an indicator of poor prognosis for patients with transitional cell carcinoma of the bladderQ73504286
Significance of the Grb2 and son of sevenless (Sos) proteins in human bladder cancer cell linesQ74336602
Using tissue adjacent to carcinoma as a normal control: an obvious but questionable practiceQ80084116
rheb, a growth factor- and synaptic activity-regulated gene, encodes a novel Ras-related proteinQ24316714
Signaling by target of rapamycin proteins in cell growth controlQ24522447
Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signalingQ24672005
The life cycle of the 26S proteasome: from birth, through regulation and function, and onto its deathQ26738549
The 26S proteasome is a multifaceted target for anti-cancer therapiesQ26795764
Cancer treatment and survivorship statistics, 2012Q27020961
Structure of the Bro1 Domain Protein BROX and Functional Analyses of the ALIX Bro1 Domain in HIV-1 BuddingQ27676148
Two Distinct Binding Modes Define the Interaction of Brox with the C-Terminal Tails of CHMP5 and CHMP4BQ27678375
Global cancer statistics, 2012Q27860501
An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein databaseQ27861106
Elevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial CarcinomaQ28084715
Regulation of translation initiation in eukaryotes: mechanisms and biological targetsQ28111696
eIF3d is an mRNA cap-binding protein that is required for specialized translation initiationQ28118876
A statistical model for identifying proteins by tandem mass spectrometryQ28186251
Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database searchQ28211385
Comprehensive molecular characterization of urothelial bladder carcinomaQ28306864
Comparative Analysis of Label-Free and 8-Plex iTRAQ Approach for Quantitative Tissue Proteomic AnalysisQ28547700
The mechanism of eukaryotic translation initiation and principles of its regulationQ29547270
UniProt: a hub for protein informationQ29547457
STRING v9.1: protein-protein interaction networks, with increased coverage and integrationQ29614691
TANDEM: matching proteins with tandem mass spectraQ29615238
Molecular mechanisms of mTOR-mediated translational controlQ29615529
Universal sample preparation method for proteome analysisQ29615662
A third-generation lentivirus vector with a conditional packaging systemQ29616120
A place for precision medicine in bladder cancer: targeting the FGFRsQ30249143
Translation initiation factor eIF3b expression in human cancer and its role in tumor growth and lung colonizationQ30416020
A uniform proteomics MS/MS analysis platform utilizing open XML file formatsQ30478423
A guided tour of the Trans-Proteomic PipelineQ30497827
Network Biomarkers of Bladder Cancer Based on a Genome-Wide Genetic and Epigenetic Network Derived from Next-Generation Sequencing DataQ31066313
Retracted: Proline-Rich Tyrosine Kinase 2 (Pyk2) Regulates IGF-I-Induced Cell Motility and Invasion of Urothelial Carcinoma CellsQ31078386
Search for the tumor-related proteins of transition cell carcinoma in Taiwan by proteomic analysisQ33231138
Differences in shotgun protein expression profile between superficial bladder transitional cell carcinoma and normal urotheliumQ33372054
The APEX Quantitative Proteomics Tool: generating protein quantitation estimates from LC-MS/MS proteomics resultsQ33391589
Analysis of secreted proteins for the study of bladder cancer cell aggressivenessQ33566081
Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapyQ33572016
Loss of 15-hydroxyprostaglandin dehydrogenase expression contributes to bladder cancer progressionQ33703804
The insulin-like growth factor receptor I promotes motility and invasion of bladder cancer cells through Akt- and mitogen-activated protein kinase-dependent activation of paxillinQ33882569
High-quality protein knowledge resource: SWISS-PROT and TrEMBL.Q33961356
Proteomic tissue profiling for the improvement of grading of noninvasive papillary urothelial neoplasiaQ34045768
The cancerous translation apparatusQ34182649
Biomarker research and some deduction in superficial bladder cancer cells combined with corresponding stromaQ34202242
Stromal proteome expression profile and muscle-invasive bladder cancer researchQ34392967
The role of eIF3 and its individual subunits in cancerQ34450907
eIF3: a versatile scaffold for translation initiation complexesQ34558903
Parallel proteomic analysis in muscle-invasive bladder transitional cell carcinoma and cancer-related stromaQ34616387
COMPASS: a suite of pre- and post-search proteomics software tools for OMSSAQ34629832
Lentivirus-mediated knockdown of eukaryotic translation initiation factor 3 subunit D inhibits proliferation of HCT116 colon cancer cellsQ34706800
Protein interactome of muscle invasive bladder cancerQ34876528
P70S6K and Elf4E dual inhibition is essential to control bladder tumor growth and progression in orthotopic mouse non-muscle invasive bladder tumor modelQ35089340
Role of the mTOR Pathway in the Progression and Recurrence of Bladder Cancer: An Immunohistochemical Tissue Microarray StudyQ35151995
The emerging importance of α-L-fucose in human breast cancer: a review.Q35172546
Far from resolved: stromal cell-based iTRAQ research of muscle-invasive bladder cancer regarding heterogeneityQ35210941
Heterogeneity research in muscle-invasive bladder cancer based on differential protein expression analysisQ35217663
The GOA database: gene Ontology annotation updates for 2015Q35253738
Decorin antagonizes IGF receptor I (IGF-IR) function by interfering with IGF-IR activity and attenuating downstream signalingQ35266398
Low ANXA10 expression is associated with disease aggressiveness in bladder cancerQ35620687
The 26S proteasome complex: an attractive target for cancer therapyQ35624079
Dual inhibition by S6K1 and Elf4E is essential for controlling cellular growth and invasion in bladder cancerQ39062692
Recent trends in incidence of five common cancers in 26 European countries since 1988: Analysis of the European Cancer ObservatoryQ39334049
Rapid mass spectrometric conversion of tissue biopsy samples into permanent quantitative digital proteome mapsQ39404529
hsa-miR-96 up-regulates MAP4K1 and IRS1 and may function as a promising diagnostic marker in human bladder urothelial carcinomasQ39459212
Human amniotic fluid-derived mesenchymal stem cells as therapeutic vehicles: a novel approach for the treatment of bladder cancer.Q39460127
Expression of CD147, BIGH3 and Stathmin and their potential role as diagnostic marker in patients with urothelial carcinoma of the bladderQ39613540
A molecular taxonomy for urothelial carcinoma.Q39621985
High dose human insulin and insulin glargine promote T24 bladder cancer cell proliferation via PI3K-independent activation of Akt.Q39624174
The role of mTOR in bladder cancerQ39769116
Comparative Tissue Proteomics of Microdissected Specimens Reveals Novel Candidate Biomarkers of Bladder CancerQ35665449
Knockdown of eIF3D inhibits breast cancer cell proliferation and invasion through suppressing the Wnt/β-catenin signaling pathwayQ36261389
Translational control in cancer etiologyQ36555212
The mTOR pathway in the control of protein synthesisQ36600753
Bladder Cancer Molecular Taxonomy: Summary from a Consensus MeetingQ37053995
Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancerQ37122307
Alterations in human breast cancer adhesion-motility in response to changes in cell surface glycoproteins displaying alpha-L-fucose moieties.Q37164814
Development of a multiplex quantitative PCR signature to predict progression in non-muscle-invasive bladder cancerQ37269864
Silencing of Profilin-1 suppresses cell adhesion and tumor growth via predicted alterations in integrin and Ca2+ signaling in T24M-based bladder cancer modelsQ37688606
Translational control in cancer.Q37717999
Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladderQ37730596
Urothelial carcinoma of the bladder: definition, treatment and future effortsQ37944437
AMPK and mTOR in cellular energy homeostasis and drug targetsQ37948152
Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet?Q37967115
Translation factors and ribosomal proteins control tumor onset and progression: how?Q38104237
Eukaryotic translation initiation factors in cancer development and progressionQ38119725
Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversityQ38297729
Alpha-L-fucose: a potentially critical molecule in pathologic processes including neoplasiaQ38332755
Targeting the translation machinery in cancerQ38368049
Chromosomal and proteome analysis of a new T24-based cell line model for aggressive bladder cancerQ38452601
Developing proteomic biomarkers for bladder cancer: towards clinical applicationQ38511509
mTOR inhibitors in urinary bladder cancer.Q38737064
Immunotherapy: a new treatment paradigm in bladder cancerQ38743589
Origins of Bladder CancerQ38747183
EIF3D silencing suppresses renal cell carcinoma tumorigenesis via inducing G2/M arrest through downregulation of Cyclin B1/CDK1 signalingQ38781713
The oncogenic role of EIF3D is associated with increased cell cycle progression and motility in prostate cancerQ38868194
Knockdown of eIF3d inhibits cell proliferation through G2/M phase arrest in non-small cell lung cancerQ38871165
RNAi-Mediated Silencing of EIF3D Alleviates Proliferation and Migration of Glioma U251 and U87MG CellsQ38909542
Knockdown of EIF3D suppresses proliferation of human melanoma cells through G2/M phase arrestQ38947243
Emerging role of mTOR in the response to cancer therapeuticsQ38964435
P4510describes a project that usesImageJQ1659584
P433issue41
P407language of work or nameEnglishQ1860
P921main subjecttumor invasionQ60750433
P304page(s)69435-69455
P577publication date2017-04-20
P1433published inOncotargetQ1573155
P1476titleProteomics analysis of bladder cancer invasion: Targeting EIF3D for therapeutic intervention
P478volume8